Bibliographic Details
| Title: |
Altered cholesterol homeostasis in critical illness-induced muscle weakness: effect of exogenous 3-hydroxybutyrate. |
| Authors: |
Goossens, Chloë, Weckx, Ruben, Derde, Sarah, Vander Perre, Sarah, Derese, Inge, Van Veldhoven, Paul P., Ghesquière, Bart, Van den Berghe, Greet, Langouche, Lies |
| Source: |
Critical Care; 8/17/2021, Vol. 25 Issue 1, p1-12, 12p |
| Subject Terms: |
MICE physiology, CHOLESTEROL metabolism, HOMEOSTASIS, 3-Hydroxybutyric acid, BIOLOGICAL models, RESEARCH, MULTIVARIATE analysis, ANIMAL experimentation, RESEARCH methodology, GENETIC disorders, MEDICAL cooperation, EVALUATION research, MUSCLE weakness, CATASTROPHIC illness, COMPARATIVE studies, RESEARCH funding, LIPID metabolism disorders, CHOLESTEROL, MICE |
| Abstract: |
Background: Muscle weakness is a complication of critical illness which hampers recovery. In critically ill mice, supplementation with the ketone body 3-hydroxybutyrate has been shown to improve muscle force and to normalize illness-induced hypocholesterolemia. We hypothesized that altered cholesterol homeostasis is involved in development of critical illness-induced muscle weakness and that this pathway can be affected by 3-hydroxybutyrate.Methods: In both human critically ill patients and septic mice, the association between circulating cholesterol concentrations and muscle weakness was assessed. In septic mice, the impact of 3-hydroxybutyrate supplementation on cholesterol homeostasis was evaluated with use of tracer technology and through analysis of markers of cholesterol metabolism and downstream pathways.Results: Serum cholesterol concentrations were lower in weak than in non-weak critically ill patients, and in multivariable analysis adjusting for baseline risk factors, serum cholesterol was inversely correlated with weakness. In septic mice, plasma cholesterol correlated positively with muscle force. In septic mice, exogenous 3-hydroxybutyrate increased plasma cholesterol and altered cholesterol homeostasis, by normalization of plasma mevalonate and elevation of muscular, but not hepatic, expression of cholesterol synthesis genes. In septic mice, tracer technology revealed that 3-hydroxybutyrate was preferentially taken up by muscle and metabolized into cholesterol precursor mevalonate, rather than TCA metabolites. The 3-hydroxybutyrate protection against weakness was not related to ubiquinone or downstream myofiber mitochondrial function, whereas cholesterol content in myofibers was increased.Conclusions: These findings point to a role for low cholesterol in critical illness-induced muscle weakness and to a protective mechanism-of-action for 3-hydroxybutyrate supplementation. [ABSTRACT FROM AUTHOR] |
|
Copyright of Critical Care is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
